| |
|
|
|
European Autism Interventions: A Multicentre Study for Developing New Medications (EU-AIMS), Wolfson Theatre, Institute of Psychiatry, Psychology and Neuroscience, 16 De Crespigny Park, London SE5 8AF
Wednesday 22 October, 6pm-8pm
What would it mean to develop medical treatment for the core features of autism? Recent research has enriched our understanding of the biology of autism, as well as the social experiences of being autistic, but the core biological features of autism are still not well understood. Any medication for the core symptoms of autism is thus still some way off in the future. Nonetheless, much research is now looking for biological markers for which treatments might be developed.
European Autism Interventions: A Multicentre Study for Developing New Medications (EU-AIMS) is a collaboration seeking new methods for the development of biological markers and drug treatments for autism. There is considerable support for such an endeavour, including from groups representing autistic people and their families and allies. However, other autistic people, some autism self-advocacy groups and some ethical and legal scholars are concerned about autism coming to be defined only as a biological disorder in need of treatment, and have called for wide debate on the relationships between biology, treatment, and difference in autism.
This public dialogue, organised by the Ethics Advisory Board of EU-AIMS, brings together autism advocates and self-advocates, psychiatrists, and ethicists to discuss these issues. This event will ask:
- What are the prospects for intervening pharmaceutically in the core features of autism in the future?
- What social and ethical issues are thrown up by this development?
- How should we balance promise and risk in seeking medical interventions, and how can questions around difference, disability and advocacy become audible within pharmacological research?
- How can a diverse range of autistic voices be heard around these questions, and how can autism researchers and autistic people come together to work through these issues?
|
|
|
|
|
|
|
|
Organized by:
|
|
European Autism Interventions: A Multicentre Study for Developing New Medications (EU-AIMS) |
|
|
Invited Speakers:
|
|
Declan Murphy (Academic Coordinator of EU-AIMS, and Professor of Psychiatry and Brain Maturation at King's College London's Institute of Psychiatry, Psychology and Neuroscience)
Richard Ashcroft (Co-Chair of the Ethics Advisory Board of EU-AIMS, and Professor of Bioethics at Queen Mary University of London's School of Law)
Ilina Singh (Co-Chair of the Ethics Advisory Board of EU-AIMS, and Professor of Science, Ethics and Society at King's College London's Department of Social Science, Health and Medicine)
Virginia Bovell (Vice-President of Ambitious about Autism, and Researcher at the Ethox Centre at the University of Oxford's Nuffield Department of Population Health)
Russell Stronach (Chair of Autistic UK)
Sandy Starr (Communications Officer at the Progress Educational Trust, and Webmaster of BioNews)
[All of the speakers listed above are confirmed]
|
|
|
|
|
|
|
|
Deadline for Abstracts:
|
|
N/A
|
|
|
|
|
|
|
|
Registration:
|
|
This event is free to attend, but advance booking is required. Please book online by clicking here.
|
|
|
E-mail:
|
|
sstarr@progress.org.uk
|
|
|
|
|
|
|
|
|